Regional Insights: North America Leading the Cancer biomarker Market
North America dominates the Cancer biomarker Market, driven by advanced healthcare infrastructure, high R&D investments, and strong regulatory support. The U.S. is a hub for biomarker-based clinical trials and innovative diagnostic solutions.
Asia-Pacific, however, is emerging as a fast-growing region due to increasing cancer prevalence, rising healthcare spending, and expanding pharmaceutical research.
Market Outlook: Globally, the cancer biomarker market was USD 15.9 billion in 2022 and will grow to USD 27.8 billion by 2030, reflecting a 9.8% CAGR.
1 View